Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $90.00, for a total value of $1,800,000.00. Following the completion of the transaction, the chief executive officer owned 206,637 shares of the company's stock, valued at approximately $18,597,330. This trade represents a 8.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christopher Peetz also recently made the following trade(s):
- On Tuesday, September 1st, Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $98.68, for a total value of $2,960,400.00.
- On Monday, August 10th, Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $98.92, for a total value of $1,978,400.00.
Mirum Pharmaceuticals Stock Performance
NASDAQ:MIRM opened at $96.97 on Thursday. The stock's fifty day moving average is $89.51 and its 200 day moving average is $98.44. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The firm has a market capitalization of $6.30 billion, a PE ratio of -6.27 and a beta of 0.75. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.38). The company had revenue of $185.72 million during the quarter, compared to the consensus estimate of $178.07 million. Mirum Pharmaceuticals had a negative return on equity of 65.71% and a negative net margin of 134.75%. The firm's quarterly revenue was up 39.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.05 earnings per share. On average, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.32 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the stock. Royal Bank Of Canada restated an "outperform" rating and issued a $155.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday. Citizens Jmp lifted their price target on shares of Mirum Pharmaceuticals from $144.00 to $167.00 and gave the stock a "market outperform" rating in a research note on Wednesday. Stifel Nicolaus upped their price target on shares of Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a "buy" rating in a report on Wednesday, October 14th. UBS Group set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $189.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $153.56.
Check Out Our Latest Analysis on Mirum Pharmaceuticals
Hedge Funds Weigh In On Mirum Pharmaceuticals
Large investors have recently bought and sold shares of the business. ABS Investment Management LLC bought a new position in Mirum Pharmaceuticals in the 2nd quarter valued at $245,847,000. Integrated Wealth Concepts LLC purchased a new stake in Mirum Pharmaceuticals in the second quarter worth $27,000. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals during the second quarter worth $44,000. State of Wyoming bought a new stake in shares of Mirum Pharmaceuticals during the second quarter worth $52,000. Finally, Summit Securities Group LLC bought a new stake in shares of Mirum Pharmaceuticals during the first quarter worth $42,000.
Mirum Pharmaceuticals News Roundup
Here are the key news stories impacting Mirum Pharmaceuticals this week:
- Positive Sentiment: Several firms raised their price targets: Citizens JMP to $167 from $144, HC Wainwright to $202 from $200, and Cantor Fitzgerald to $160 from $155. RBC reaffirmed its “outperform” rating and $155 target. The favorable analyst outlook is a likely driver of the stock’s strength. Citizens JMP recommendations HC Wainwright recommendations Cantor Fitzgerald recommendations RBC rating report
- Positive Sentiment: Third-quarter revenue rose 39.6% year over year to $185.72 million, exceeding analyst expectations of about $178 million. Mirum Q3 results and business update
- Positive Sentiment: Mirum also announced new data across its rare liver disease portfolio for presentation at AASLD’s The Liver Meeting, a potential source of investor interest in its pipeline. AASLD portfolio data announcement
- Negative Sentiment: The company reported a Q3 loss of $0.87 per share, wider than the roughly $0.49–$0.53 loss analysts expected, and below the $0.05 per-share profit a year earlier. This earnings miss tempers the positive revenue and analyst news. Q3 earnings report
Mirum Pharmaceuticals Company Profile
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company's medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.
Mirum's lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
